{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:36Z","timestamp":1793386476728,"version":"4.5.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Myaware"},{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The last 10\u00a0years has brought transformative developments in the effective treatment of myasthenia gravis (MG). Beginning with the randomized trial of thymectomy in myasthenia gravis that demonstrated efficacy of thymectomy in nonthymomatous MG, several new treatment approaches have completed successful clinical trials and regulatory launch. These modalities, including B cell depletion, complement inhibition, and blockade of the neonatal Fc receptor, are now in use, offering prospects of sustained remission and neuromuscular protection in what is a long-term disease. In this review, we update our clinico-immunological review of 2016 with these important advances, examine their role in treatment algorithms, and focus attention on key issues of biomarkers for prognostication and the growing cohort of older patients, both those with long-term disease, and late-onset MG (\u2018LOMG\u2019). We close by expressing our four hopes for the next 5\u201310\u00a0years: improvements in laboratory medicine to facilitate rapid diagnosis, effective strategies for neuromuscular protection, more research into and better understanding of pathophysiology and treatment response in older individuals, and the potentially transformative role of therapies aimed at delivering a durable response such as chimeric antigen receptor (CAR) T cells. Our postscript summarizes some emerging themes in the field of serological and online biomarkers, which may develop greater stature in the next epoch.<\/jats:p>","DOI":"10.1007\/s00415-025-12922-7","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:51:02Z","timestamp":1740243062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Myasthenia gravis in 2025: five new things and four hopes for the future"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5998","authenticated-orcid":false,"given":"S. N. M.","family":"Binks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1787-0497","authenticated-orcid":false,"given":"I. M.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-6822","authenticated-orcid":false,"given":"Mohammad","family":"Ashraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2395-8695","authenticated-orcid":false,"given":"A.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-2667","authenticated-orcid":false,"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-9855","authenticated-orcid":false,"given":"M Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"12922_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/nejmoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511\u2013522. https:\/\/doi.org\/10.1056\/nejmoa1602489","journal-title":"N Engl J Med"},{"key":"12922_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, et al (1998) Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769\u2013772. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x","journal-title":"Ann N Y Acad Sci"},{"key":"12922_CR3","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","volume":"64","author":"RS Bedlack","year":"2005","unstructured":"Bedlack RS, Simel DL, Bosworth HSDB (2005) Myasthenia gravis score\u202f: assessment of responsiveness and. Neurology 64:1968\u20131970","journal-title":"Neurology"},{"key":"12922_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","volume":"18","author":"GI Wolfe","year":"2019","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2019) Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 18:259\u2013268. https:\/\/doi.org\/10.1016\/S1474-4422(18)30392-2","journal-title":"Lancet Neurol"},{"key":"12922_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010031","author":"I Lee","year":"2020","unstructured":"Lee I, Kuo HC, Aban IB et al (2020) Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000010031","journal-title":"Neurology"},{"key":"12922_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P et al (2015) Myasthenia gravis: association of british neurologists\u2019 management guidelines. Pract Neurol 15:199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"key":"12922_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3978\/j.issn.2225-319X.2015.07.03","volume":"4","author":"PG Rowse","year":"2015","unstructured":"Rowse PG, Roden AC, Corl FM et al (2015) Minimally invasive thymectomy: the mayo Clinic experience. Ann Cardiothorac Surg 4:519\u2013526. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2015.07.03","journal-title":"Ann Cardiothorac Surg"},{"key":"12922_CR8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/ejcts\/ezab014","volume":"60","author":"CL Wilshire","year":"2021","unstructured":"Wilshire CL, Blitz SL, Fuller CC et al (2021) Minimally invasive thymectomy for myasthenia gravis favours left-sided approach and low severity class. Eur J Cardio-Thoracic Surg 60:898\u2013905. https:\/\/doi.org\/10.1093\/ejcts\/ezab014","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"12922_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.athoracsur.2021.06.071","volume":"113","author":"SM Raja","year":"2022","unstructured":"Raja SM, Guptill JT, McConnell A et al (2022) Perioperative outcomes of thymectomy in myasthenia gravis: a thoracic surgery database analysis. Ann Thorac Surg 113:904\u2013910. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.06.071","journal-title":"Ann Thorac Surg"},{"key":"12922_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3978\/j.issn.2225-319X.2016.01.01","volume":"5","author":"NR Hess","year":"2016","unstructured":"Hess NR, Sarkaria IS, Pennathur A et al (2016) Minimally invasive versus open thymectomy: A systematic review of surgical techniques, patient demographics, and perioperative outcomes. Ann Cardiothorac Surg 5:1\u20139. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2016.01.01","journal-title":"Ann Cardiothorac Surg"},{"key":"12922_CR11","doi-asserted-by":"publisher","DOI":"10.21037\/ACS.2019.02.04","author":"KE O\u2019Sullivan","year":"2019","unstructured":"O\u2019Sullivan KE, Kreaden US, Hebert AE et al (2019) A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy. Ann Cardiothorac Surg. https:\/\/doi.org\/10.21037\/ACS.2019.02.04","journal-title":"Ann Cardiothorac Surg"},{"key":"12922_CR12","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s00464-022-09757-y","volume":"37","author":"Y Lee","year":"2023","unstructured":"Lee Y, Samarasinghe Y, Patel J et al (2023) The short and long-term effects of open vs minimally invasive thymectomy in myasthenia gravis patients: a systematic review and meta-analysis. Surg Endosc 37:3321\u20133339. https:\/\/doi.org\/10.1007\/s00464-022-09757-y","journal-title":"Surg Endosc"},{"key":"12922_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41379-022-01070-2","volume":"35","author":"J Sarkkinen","year":"2022","unstructured":"Sarkkinen J, Dunkel J, Tuulasvaara A et al (2022) Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy. Mod Pathol 35:1168\u20131174. https:\/\/doi.org\/10.1038\/s41379-022-01070-2","journal-title":"Mod Pathol"},{"key":"12922_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/mus.26096","volume":"58","author":"E Klimiec","year":"2018","unstructured":"Klimiec E, Quirke M, Leite MI, Hilton-Jones D (2018) Thymus imaging in myasthenia gravis: the relevance in clinical practice. Mus Nerve 58:1531\u201356. https:\/\/doi.org\/10.1002\/mus.26096","journal-title":"Mus Nerve"},{"key":"12922_CR15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"12922_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"12922_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00383-017-4086-3","volume":"33","author":"AL Madenci","year":"2017","unstructured":"Madenci AL, Li GZ, Weil BR et al (2017) The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int 33:683\u2013694. https:\/\/doi.org\/10.1007\/s00383-017-4086-3","journal-title":"Pediatr Surg Int"},{"key":"12922_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.nmd.2021.09.013","volume":"31","author":"WC Ng","year":"2021","unstructured":"Ng WC, Hartley L (2021) Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomes. Neuromuscul Disord 31:1113\u20131123. https:\/\/doi.org\/10.1016\/j.nmd.2021.09.013","journal-title":"Neuromuscul Disord"},{"key":"12922_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J (2016) Myasthenia gravis: a clinical-immunological update. J Neurol 263:826\u2013834. https:\/\/doi.org\/10.1007\/s00415-015-7963-5","journal-title":"J Neurol"},{"key":"12922_CR20","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86:255\u2013260","journal-title":"Yale J Biol Med"},{"key":"12922_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F et al (2022) Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 9:122\u2013131. https:\/\/doi.org\/10.1002\/acn3.51492","journal-title":"Ann Clin Transl Neurol"},{"key":"12922_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awy010","volume":"141","author":"R Wilson","year":"2018","unstructured":"Wilson R, Makuch M, Kienzler AK et al (2018) Condition-dependent generation of aquaporin-4 antibodies from circulating b cells in neuromyelitis optica. Brain 141:1063\u20131074. https:\/\/doi.org\/10.1093\/brain\/awy010","journal-title":"Brain"},{"key":"12922_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2567.1999.00799.x","volume":"97","author":"ME Hill","year":"1999","unstructured":"Hill ME, Ferguson DJP, Austyn JM et al (1999) Potent immunostimulatory dendritic cells can be cultured in bulk from progenitors in normal infant and adult myasthenic human thymus. Immunology 97:325\u2013332","journal-title":"Immunology"},{"key":"12922_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","volume":"57","author":"MI Leite","year":"2005","unstructured":"Leite MI, Scr\u00f6bel P, Jones M et al (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57:444\u2013448. https:\/\/doi.org\/10.1002\/ana.20386","journal-title":"Ann Neurol"},{"key":"12922_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","volume":"171","author":"MI Leite","year":"2007","unstructured":"Leite MI, Jones M, Str\u00f6bel P et al (2007) Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 171:893\u2013905. https:\/\/doi.org\/10.2353\/ajpath.2007.070240","journal-title":"Am J Pathol"},{"key":"12922_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard","year":"2018","unstructured":"Howard JF (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113\u2013128. https:\/\/doi.org\/10.1111\/nyas.13522","journal-title":"Ann N Y Acad Sci"},{"key":"12922_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"12922_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011207","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S et al (2021) Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during regain and its open-label extension. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","journal-title":"Neurology"},{"key":"12922_CR29","unstructured":"US Food and Drug Administration (2019) SOLIRIS\u00ae (eculizumab) injection, for intravenous use: Full Prescribing Information. 1\u201342"},{"key":"12922_CR30","unstructured":"European Medicines Agency (2017) Soliris\/eculizumab summary of opinion (post authorisation)"},{"key":"12922_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/evidoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1:1\u201312. https:\/\/doi.org\/10.1056\/evidoa2100066","journal-title":"NEJM Evid"},{"key":"12922_CR32","unstructured":"US food and drug administration (2018) Ultomiris: Full prescribing information (Ravulizumab-cwvz). 1\u201318"},{"key":"12922_CR33","volume":"1","author":"EM Agency","year":"2022","unstructured":"European Medicines Agency (2022) ULTOMIRIS (ravulizumab) Summary of opinion","journal-title":"ULTOMIRIS (ravulizumab)"},{"key":"12922_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"12922_CR35","unstructured":"US food and drug Administration (2023) ZILBRYSQ (zilucoplan) injection, for subcutaneous use Initial U.S. Approval: 2023"},{"key":"12922_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000209888","volume":"103","author":"M Ringelstein","year":"2024","unstructured":"Ringelstein M, Asseyer S, Lindenblatt G et al (2024) Eculizumab use in neuromyelitis optica spectrum disorders routine clinical care data from a european cohort. Neurology 103:1\u201316. https:\/\/doi.org\/10.1212\/WNL.0000000000209888","journal-title":"Neurology"},{"key":"12922_CR37","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264. https:\/\/doi.org\/10.1038\/nbt1344","journal-title":"Nat Biotechnol"},{"key":"12922_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M (2024) Zilucoplan: first approval. Drugs 84:99\u2013104. https:\/\/doi.org\/10.1007\/s40265-023-01977-3","journal-title":"Drugs"},{"key":"12922_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2023.12.004","author":"S Jindal","year":"2024","unstructured":"Jindal S, Pedersen DV, Gera N et al (2024) Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. https:\/\/doi.org\/10.1016\/j.molimm.2023.12.004","journal-title":"Mol Immunol"},{"key":"12922_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE et al (2023) Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"key":"12922_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269749","author":"K Devalaraja-Narashimha","year":"2022","unstructured":"Devalaraja-Narashimha K, Huang C, Cao M et al (2022) Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0269749","journal-title":"PLoS ONE"},{"key":"12922_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.748","author":"A Gaya","year":"2023","unstructured":"Gaya A, Munir T, Urbano-Ispizua A et al (2023) Results of a phase 1\/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. J Haem. https:\/\/doi.org\/10.1002\/jha2.748","journal-title":"J Haem"},{"key":"12922_CR43","unstructured":"US Food and Drug Administration (2021) VYVGART TM (efgartigimod alfa-fcab) injection, for intravenous use"},{"key":"12922_CR44","unstructured":"European Medicines Agency (2022) Vyvgart (efgartigimod alfa). Summary of opinion"},{"key":"12922_CR45","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"12922_CR46","unstructured":"UCB Group of Companies (2023) Highlights of prescribing information-rozanolixizumab"},{"key":"12922_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"12922_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"key":"12922_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714","author":"JH Leu","year":"2024","unstructured":"Leu JH, Vermeulen A, Abbes C et al (2024) Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2024.1302714","journal-title":"Front Neurosci"},{"key":"12922_CR50","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/cts.13019","volume":"14","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, Hai J, Lee PCH et al (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci 14:1769\u20131779. https:\/\/doi.org\/10.1111\/cts.13019","journal-title":"Clin Transl Sci"},{"key":"12922_CR51","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan R-S, Yang H et al (2022) Therapeutic effects of batoclimab in chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther 11:815\u2013834. https:\/\/doi.org\/10.1007\/s40120-022-00345-9","journal-title":"Neurol Ther"},{"key":"12922_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014574","author":"KC Dodd","year":"2023","unstructured":"Dodd KC, Clay FJ, Forbes AM et al (2023) Rituximab for myasthenia gravis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD014574","journal-title":"Cochrane Database Syst Rev"},{"key":"12922_CR53","first-page":"1","volume":"170084P","author":"NHS England","year":"2021","unstructured":"NHS England (2021) Clinical commissioning policy statement: rituximab bio-similar for the treatment of myasthenia gravis (adults) (version 2). NHS Engl Com Rep Ref 170084P:1\u201313","journal-title":"NHS Engl Com Rep Ref"},{"key":"12922_CR54","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the rinomax randomized clinical trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"12922_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2022) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"12922_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394:1352\u20131363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"key":"12922_CR57","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X et al (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"12922_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead265","author":"D Xu","year":"2023","unstructured":"Xu D, Fang J, Zhang S et al (2023) Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kead265","journal-title":"Rheumatology"},{"key":"12922_CR59","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381:2114\u20132124. https:\/\/doi.org\/10.1056\/NEJMoa1901747","journal-title":"N Engl J Med"},{"key":"12922_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19:402\u2013412. https:\/\/doi.org\/10.1016\/S1474-4422(20)30078-8","journal-title":"Lancet Neurol"},{"key":"12922_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X (2023) New and emerging treatments for myasthenia gravis. BMJ Med. https:\/\/doi.org\/10.1136\/bmjmed-2022-000241","journal-title":"BMJ Med"},{"key":"12922_CR62","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M et al (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol 22:578\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(23)00194-1","journal-title":"Lancet Neurol"},{"key":"12922_CR63","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S et al (2023) Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol 41:1229\u20131238. https:\/\/doi.org\/10.1038\/s41587-022-01637-z","journal-title":"Nat Biotechnol"},{"key":"12922_CR64","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A et al (2024) Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol 11:1338\u20131346. https:\/\/doi.org\/10.1002\/acn3.52051","journal-title":"Ann Clin Transl Neurol"},{"key":"12922_CR65","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","volume":"17","author":"JD L\u00fcnemann","year":"2021","unstructured":"L\u00fcnemann JD (2021) Getting specific: targeting Fc receptors in myasthenia gravis. Nat Rev Neurol 17:597\u2013598. https:\/\/doi.org\/10.1038\/s41582-021-00547-z","journal-title":"Nat Rev Neurol"},{"key":"12922_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H et al (2022) Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 21:189\u2013202. https:\/\/doi.org\/10.1016\/S1474-4422(21)00463-4","journal-title":"Lancet Neurol"},{"key":"12922_CR67","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40120-023-00464-x","volume":"12","author":"A Regnault","year":"2023","unstructured":"Regnault A, Morel T, de la Loge C et al (2023) Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO. Neurol Ther 12:1573\u20131590. https:\/\/doi.org\/10.1007\/s40120-023-00464-x","journal-title":"Neurol Ther"},{"key":"12922_CR68","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y et al (2024) Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol 81:336\u2013345. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044","journal-title":"JAMA Neurol"},{"key":"12922_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15:113\u2013124. https:\/\/doi.org\/10.1038\/s41582-018-0110-z","journal-title":"Nat Rev Neurol"},{"key":"12922_CR70","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"12922_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E et al (2023) Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757","journal-title":"Front Immunol"},{"key":"12922_CR72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M et al (2023) The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol 14:19\u201327. https:\/\/doi.org\/10.1111\/cen3.12739","journal-title":"Clin Exp Neuroimmunol"},{"key":"12922_CR73","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:259\u2013261. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"12922_CR74","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/14656566.2022.2122710","volume":"23","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis? Expert Opin Pharmacother 23:1471\u20131474. https:\/\/doi.org\/10.1080\/14656566.2022.2122710","journal-title":"Expert Opin Pharmacother"},{"key":"12922_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"12922_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000500268","volume":"53","author":"P Maddison","year":"2019","unstructured":"Maddison P, Ambrose PA, Sadalage G, Vincent A (2019) A prospective study of the incidence of myasthenia gravis in the East Midlands of England. Neuroepidemiology 53:93\u201399. https:\/\/doi.org\/10.1159\/000500268","journal-title":"Neuroepidemiology"},{"key":"12922_CR77","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM et al (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21:176\u2013188. https:\/\/doi.org\/10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"12922_CR78","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72:989\u2013995. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1276","journal-title":"JAMA Neurol"},{"key":"12922_CR79","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/nejmoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S et al (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639. https:\/\/doi.org\/10.1056\/nejmoa1311084","journal-title":"N Engl J Med"},{"key":"12922_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","volume":"292","author":"T Punga","year":"2016","unstructured":"Punga T, Bartoccioni E, Lewandowska M et al (2016) Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J Neuroimmunol 292:21\u201326. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.003","journal-title":"J Neuroimmunol"},{"key":"12922_CR81","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","volume":"356","author":"AR Punga","year":"2015","unstructured":"Punga AR, Andersson M, Alimohammadi M, Punga T (2015) Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J Neurol Sci 356:90\u201396. https:\/\/doi.org\/10.1016\/j.jns.2015.06.019","journal-title":"J Neurol Sci"},{"key":"12922_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000450","author":"CJ Molin","year":"2018","unstructured":"Molin CJ, Sabre L, Weis C-A et al (2018) Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol Neuroimmunol Neuroinflammation. https:\/\/doi.org\/10.1212\/nxi.0000000000000450","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"12922_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577383","author":"H Zhong","year":"2020","unstructured":"Zhong H, Lu J, Jing S et al (2020) Low-dose rituximab lowers serum exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577383","journal-title":"J Neuroimmunol"},{"key":"12922_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104388","author":"P Cavalcante","year":"2019","unstructured":"Cavalcante P, Mizrachi T, Barzago C et al (2019) MicroRNA signature associated with treatment response in myasthenia gravis: a further step towards precision medicine. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2019.104388","journal-title":"Pharmacol Res"},{"key":"12922_CR85","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","volume":"321","author":"L Sabre","year":"2018","unstructured":"Sabre L, Maddison P, Sadalage G et al (2018) Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. J Neuroimmunol 321:164\u2013170. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.05.003","journal-title":"J Neuroimmunol"},{"key":"12922_CR86","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/acn3.692","volume":"6","author":"L Sabre","year":"2019","unstructured":"Sabre L, Maddison P, Wong SH et al (2019) miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Ann Clin Transl Neurol 6:243\u2013251. https:\/\/doi.org\/10.1002\/acn3.692","journal-title":"Ann Clin Transl Neurol"},{"key":"12922_CR87","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jocn.2006.07.006","volume":"15","author":"S Munakata","year":"2008","unstructured":"Munakata S, Chen M, Aosai F et al (2008) The clinical significance of anti-heat shock cognate protein 71 antibody in myasthenia gravis. J Clin Neurosci 15:158\u2013165. https:\/\/doi.org\/10.1016\/j.jocn.2006.07.006","journal-title":"J Clin Neurosci"},{"key":"12922_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1756130","author":"J Thanner","year":"2020","unstructured":"Thanner J, Bekos C, Veraar C et al (2020) Heat shock protein 90\u03b1 in thymic epithelial tumors and non-thymomatous myasthenia gravis. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2020.1756130","journal-title":"Oncoimmunology"},{"key":"12922_CR89","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jneuroim.2010.04.024","volume":"225","author":"G Helgeland","year":"2010","unstructured":"Helgeland G, Petzold A, Hoff JM et al (2010) Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barr\u00e9 syndrome. J Neuroimmunol 225:180\u2013183. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.04.024","journal-title":"J Neuroimmunol"},{"key":"12922_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1056322","author":"F Stascheit","year":"2023","unstructured":"Stascheit F, Aigner A, Mergenthaler P et al (2023) Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case\u2013Control study. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.1056322","journal-title":"Front Neurol"},{"key":"12922_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2018.02627","volume":"9","author":"D Qiu","year":"2018","unstructured":"Qiu D, Xia Z, Jiao X et al (2018) Altered gut microbiota in myasthenia gravis. Front Microbiol 9:1\u201310. https:\/\/doi.org\/10.3389\/fmicb.2018.02627","journal-title":"Front Microbiol"},{"key":"12922_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-32700-y","volume":"8","author":"G Moris","year":"2018","unstructured":"Moris G, Arboleya S, Mancabelli L et al (2018) Fecal microbiota profile in a group of myasthenia gravis patients. Sci Rep 8:1\u20138. https:\/\/doi.org\/10.1038\/s41598-018-32700-y","journal-title":"Sci Rep"},{"key":"12922_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211035657","author":"A Totzeck","year":"2021","unstructured":"Totzeck A, Ramakrishnan E, Schlag M et al (2021) Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864211035657","journal-title":"Ther Adv Neurol Disord"},{"key":"12922_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1248336","author":"X-J Ding","year":"2023","unstructured":"Ding X-J, Li H-Y, Wang H et al (2023) Altered gut microbiota and metabolites in untreated myasthenia gravis patients. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2023.1248336","journal-title":"Front Neurol"},{"key":"12922_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-023-01163-8","volume":"13","author":"T Su","year":"2023","unstructured":"Su T, Yin X, Ren J et al (2023) Causal relationship between gut microbiota and myasthenia gravis: a bidirectional mendelian randomization study. Cell Biosci 13:1\u201311. https:\/\/doi.org\/10.1186\/s13578-023-01163-8","journal-title":"Cell Biosci"},{"key":"12922_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201901441","author":"P Zheng","year":"2019","unstructured":"Zheng P, Li Y, Wu J et al (2019) Perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome. Adv Sci. https:\/\/doi.org\/10.1002\/advs.201901441","journal-title":"Adv Sci"},{"key":"12922_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2020.564579","volume":"11","author":"X Tan","year":"2020","unstructured":"Tan X, Huang Y, Chai T et al (2020) Differential gut microbiota and fecal metabolites related with the clinical subtypes of myasthenia Gravis. Front Microbiol 11:1\u201312. https:\/\/doi.org\/10.3389\/fmicb.2020.564579","journal-title":"Front Microbiol"},{"key":"12922_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-017-0891-5","volume":"17","author":"G Rakocevic","year":"2017","unstructured":"Rakocevic G, Moster M, Floeter MK (2017) Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment? BMC Neurol 17:1\u20133. https:\/\/doi.org\/10.1186\/s12883-017-0891-5","journal-title":"BMC Neurol"},{"key":"12922_CR99","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/mus.25174","volume":"54","author":"M Baruca","year":"2016","unstructured":"Baruca M, Leonardis L, Podnar S et al (2016) Single fiber EMG as a prognostic tool in myasthenia gravis. Mus Ner 54:1034\u20131040. https:\/\/doi.org\/10.1002\/mus.25174","journal-title":"Mus Ner"},{"key":"12922_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2023.1144183","volume":"14","author":"S Steyaert","year":"2023","unstructured":"Steyaert S, Lootus M, Sarabu C et al (2023) A decentralized, prospective, observational study to collect real-world data from patients with myasthenia gravis using smartphones. Front Neurol 14:1\u201312. https:\/\/doi.org\/10.3389\/fneur.2023.1144183","journal-title":"Front Neurol"},{"key":"12922_CR101","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM et al (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67:505\u2013507. https:\/\/doi.org\/10.1212\/01.wnl.0000228225.23349.5d","journal-title":"Neurology"},{"key":"12922_CR102","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.26609","volume":"60","author":"JD Triplett","year":"2019","unstructured":"Triplett JD, Hardy TA, Riminton DS et al (2019) Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: a marker of relapse? Mus Nerve 60:307\u2013311. https:\/\/doi.org\/10.1002\/mus.26609","journal-title":"Mus Nerve"},{"key":"12922_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-022-01454-0","volume":"10","author":"ML Fichtner","year":"2022","unstructured":"Fichtner ML, Hoehn KB, Ford EE et al (2022) Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathol Commun 10:1\u201316. https:\/\/doi.org\/10.1186\/s40478-022-01454-0","journal-title":"Acta Neuropathol Commun"},{"key":"12922_CR104","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","volume":"30","author":"A Meisel","year":"2023","unstructured":"Meisel A, Baggi F, Behin A et al (2023) Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal. Eur J Neurol 30:266\u2013282","journal-title":"Eur J Neurol"},{"key":"12922_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","volume":"291","author":"MG Huijbers","year":"2016","unstructured":"Huijbers MG, Vink AFD, Niks EH et al (2016) Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol 291:82\u201388. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.12.016","journal-title":"J Neuroimmunol"},{"key":"12922_CR106","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","author":"K Takata","year":"2019","unstructured":"Takata K, Stathopoulos P, Cao M et al (2019) Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.127167","journal-title":"JCI Insight"},{"key":"12922_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.12.005","volume":"244","author":"S Mori","year":"2012","unstructured":"Mori S, Yamada S, Kubo S et al (2012) Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 244:1\u20137. https:\/\/doi.org\/10.1016\/j.jneuroim.2011.12.005","journal-title":"J Neuroimmunol"},{"key":"12922_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000547","volume":"6","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Vergoossen DL, Filli\u00e9-Grijpma YE et al (2019) MuSK myasthenia gravis monoclonal antibodies: valency dictates pathogenicity. Neurol Neuroimmunol NeuroInflammation 6:1\u201310. https:\/\/doi.org\/10.1212\/NXI.0000000000000547","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"12922_CR109","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200147","author":"M Cao","year":"2023","unstructured":"Cao M, Liu W-W, Maxwell S et al (2023) IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation. Neurol Neuroimmunol Neuroinflammation. https:\/\/doi.org\/10.1212\/NXI.0000000000200147","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"12922_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny I, Cossins J, Waters P et al (2013) MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS ONE 8:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0080695","journal-title":"PLoS ONE"},{"key":"12922_CR111","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.94263","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O\u2019Connor KC (2017) Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.94263","journal-title":"JCI Insight"},{"key":"12922_CR112","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.136471","author":"R Jiang","year":"2020","unstructured":"Jiang R, Fichtner ML, Hoehn KB et al (2020) Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.136471","journal-title":"JCI Insight"},{"key":"12922_CR113","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","volume":"29","author":"F Marcuse","year":"2022","unstructured":"Marcuse F, Brandts L, Moens D et al (2022) The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis. Eur J Neurol 29:1187\u20131197. https:\/\/doi.org\/10.1111\/ene.15238","journal-title":"Eur J Neurol"},{"key":"12922_CR114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R et al (2023) Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol 146:319\u2013336","journal-title":"Acta Neuropathol"},{"key":"12922_CR115","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","volume":"144","author":"N Rose","year":"2022","unstructured":"Rose N, Holdermann S, Callegari I et al (2022) Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol 144:1005\u20131025. https:\/\/doi.org\/10.1007\/s00401-022-02493-6","journal-title":"Acta Neuropathol"},{"key":"12922_CR116","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","volume":"74","author":"KR Robeson","year":"2017","unstructured":"Robeson KR, Kumar A, Keung B et al (2017) Durability of the rituximab response in acetylcholine receptor autoantibody-positivemyasthenia gravis. JAMA Neurol 74:60\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4190","journal-title":"JAMA Neurol"},{"key":"12922_CR117","doi-asserted-by":"publisher","first-page":"30649","DOI":"10.1073\/pnas.2007206117","volume":"117","author":"R Jiang","year":"2020","unstructured":"Jiang R, Hoehn KB, Lee CS et al (2020) Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proc Natl Acad Sci U S A 117:30649\u201330660. https:\/\/doi.org\/10.1073\/pnas.2007206117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12922_CR118","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ene.15730","volume":"30","author":"F Stascheit","year":"2023","unstructured":"Stascheit F, Chuquisana O, Keller CW et al (2023) Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis. Eur J Neurol 30:1409\u20131416","journal-title":"Eur J Neurol"},{"key":"12922_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264489","author":"ML Fichtner","year":"2022","unstructured":"Fichtner ML, Hoarty MD, Vadysirisack DD et al (2022) Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0264489","journal-title":"PLoS ONE"},{"key":"12922_CR120","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001169","author":"AH Obaid","year":"2022","unstructured":"Obaid AH, Zografou C, Vadysirisack DD et al (2022) Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis. Neurol Neuroimmunol NeuroInflammation. https:\/\/doi.org\/10.1212\/NXI.0000000000001169","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"12922_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577634","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y et al (2021) High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577634","journal-title":"J Neuroimmunol"},{"key":"12922_CR122","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","volume":"27","author":"DI Jonsson","year":"2017","unstructured":"Jonsson DI, Pirskanen R, Piehl F (2017) Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord 27:565\u2013568. https:\/\/doi.org\/10.1016\/j.nmd.2017.03.007","journal-title":"Neuromuscul Disord"},{"key":"12922_CR123","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/JIR.S423098","volume":"16","author":"TT Yang","year":"2023","unstructured":"Yang TT, Wang ZY, Fan ZX et al (2023) A Pilot study on tocilizumab in very-late-onset myasthenia gravis. J Inflamm Res 16:5835\u20135843. https:\/\/doi.org\/10.2147\/JIR.S423098","journal-title":"J Inflamm Res"},{"key":"12922_CR124","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2023.0528","author":"D Jia","year":"2024","unstructured":"Jia D, Zhang F, Li H et al (2024) Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized myasthenia gravis. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2023.0528","journal-title":"Aging Dis"},{"key":"12922_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cns.14793","volume":"30","author":"Z Ruan","year":"2024","unstructured":"Ruan Z, Tang Y, Gao T et al (2024) Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. CNS Neurosci Ther 30:1\u201311. https:\/\/doi.org\/10.1111\/cns.14793","journal-title":"CNS Neurosci Ther"},{"key":"12922_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1114667","author":"JL Bennett","year":"2023","unstructured":"Bennett JL, Fujihara K, Kim HJ et al (2023) SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2023.1114667","journal-title":"Front Neurol"},{"key":"12922_CR127","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","volume":"24","author":"M K\u00fcnzli","year":"2023","unstructured":"K\u00fcnzli M, Masopust D (2023) CD4+ T cell memory. Nat Immunol 24:903\u2013914. https:\/\/doi.org\/10.1038\/s41590-023-01510-4","journal-title":"Nat Immunol"},{"key":"12922_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1126\/SCIIMMUNOL.ABA9953","volume":"5","author":"J Rasouli","year":"2020","unstructured":"Rasouli J, Casella G, Yoshimura S et al (2020) A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation. Sci Immunol 5:27\u201331. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.ABA9953","journal-title":"Sci Immunol"},{"key":"12922_CR129","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, Krishnarajah S, Kramer M et al (2021) Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol 141:901\u2013915. https:\/\/doi.org\/10.1007\/s00401-021-02299-y","journal-title":"Acta Neuropathol"},{"key":"12922_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000945","volume":"8","author":"S Ashida","year":"2021","unstructured":"Ashida S, Ochi H, Hamatani M et al (2021) Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity. Neurol Neuroimmunol NeuroInflammation 8:1\u201310. https:\/\/doi.org\/10.1212\/NXI.0000000000000945","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"12922_CR131","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","volume":"196","author":"Y Cao","year":"2016","unstructured":"Cao Y, Amezquita RA, Kleinstein SH et al (2016) Autoreactive T Cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3, and GM-CSF and diminished IL-10 production. J Immunol 196:2075\u20132084. https:\/\/doi.org\/10.4049\/jimmunol.1501339","journal-title":"J Immunol"},{"key":"12922_CR132","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/acn3.51312","volume":"8","author":"X Huan","year":"2021","unstructured":"Huan X, Luo S, Zhong H et al (2021) In-depth peripheral CD4+ T profile correlates with myasthenic crisis. Ann Clin Transl Neurol 8:749\u2013762. https:\/\/doi.org\/10.1002\/acn3.51312","journal-title":"Ann Clin Transl Neurol"},{"key":"12922_CR133","unstructured":"Carr AS (2015) Actual World Epidemiology of Myasthenia Gravis. In: Mineo T (ed) Novel challenges in myasthenia gravis. Nova Science Publishers, Inc"},{"key":"12922_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274161","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y et al (2022) Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0274161","journal-title":"PLoS ONE"},{"key":"12922_CR135","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J et al (2023) Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord 33:324\u2013333. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","journal-title":"Neuromuscul Disord"},{"key":"12922_CR136","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1749-6632.1981.tb33765.x","volume":"377","author":"MS Cohen","year":"1981","unstructured":"Cohen MS, Younger D (1981) Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci 377:670\u2013677. https:\/\/doi.org\/10.1111\/j.1749-6632.1981.tb33765.x","journal-title":"Ann N Y Acad Sci"},{"key":"12922_CR137","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010209","author":"M Tomschik","year":"2020","unstructured":"Tomschik M, Hilger E, Rath J et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000010209","journal-title":"Neurology"},{"key":"12922_CR138","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","volume":"30","author":"E Westerberg","year":"2020","unstructured":"Westerberg E, Punga AR (2020) Mortality rates and causes of death in Swedish Myasthenia Gravis patients. Neuromuscul Disord 30:815\u2013824. https:\/\/doi.org\/10.1016\/j.nmd.2020.08.355","journal-title":"Neuromuscul Disord"},{"key":"12922_CR139","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mus.24697","volume":"53","author":"JS Hansen","year":"2016","unstructured":"Hansen JS, Danielsen DH, Somnier FE et al (2016) Mortality in myasthenia gravis: A nationwide population-based follow-up study in Denmark. Mus Nerve 53:73\u201377. https:\/\/doi.org\/10.1002\/mus.24697","journal-title":"Mus Nerve"},{"key":"12922_CR140","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","volume":"48","author":"A Evoli","year":"2000","unstructured":"Evoli A, Batocchi AP, Minisci C et al (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 48:1442\u20131448. https:\/\/doi.org\/10.1111\/j.1532-5415.2000.tb02635.x","journal-title":"J Am Geriatr Soc"},{"key":"12922_CR141","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","volume":"64","author":"J Vijayan","year":"2021","unstructured":"Vijayan J, Menon D, Barnett C et al (2021) Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Mus Nerve 64:462\u2013466. https:\/\/doi.org\/10.1002\/mus.27369","journal-title":"Mus Nerve"},{"key":"12922_CR142","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s10072-021-05599-z","volume":"43","author":"Y Li","year":"2022","unstructured":"Li Y, Dong X, Li Z et al (2022) Characteristics of myasthenia gravis in elderly patients: a retrospective study. Neurol Sci 43:2775\u20132783","journal-title":"Neurol Sci"},{"key":"12922_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","volume":"325","author":"MA Hellmann","year":"2013","unstructured":"Hellmann MA, Mosberg-Galili R, Steiner I (2013) Myasthenia gravis in the elderly. J Neurol Sci 325:1\u20135. https:\/\/doi.org\/10.1016\/j.jns.2012.10.028","journal-title":"J Neurol Sci"},{"key":"12922_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2016.02.004","author":"W Sakai","year":"2016","unstructured":"Sakai W, Matsui N, Ishida M et al (2016) Late-onset myasthenia gravis is predisposed to become generalized in the elderly. NeurologicalSci. https:\/\/doi.org\/10.1016\/j.ensci.2016.02.004","journal-title":"NeurologicalSci"},{"key":"12922_CR145","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B et al (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548\u20131554. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a41211","journal-title":"Neurology"},{"key":"12922_CR146","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","volume":"282","author":"RHP de Meel","year":"2015","unstructured":"de Meel RHP, Lipka AF, van Zwet EW et al (2015) Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol 282:123\u2013125. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.03.018","journal-title":"J Neuroimmunol"},{"key":"12922_CR147","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38:497\u2013537","journal-title":"Mt Sinai J Med"},{"key":"12922_CR148","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Mus Nerve 37:141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Mus Nerve"},{"key":"12922_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S et al (2022) A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol 22:1\u201310. https:\/\/doi.org\/10.1186\/s12883-022-02692-4","journal-title":"BMC Neurol"},{"key":"12922_CR150","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S et al (2023) Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445","journal-title":"BMJ Open"},{"key":"12922_CR151","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ane.13549","volume":"145","author":"E Klimiec-Moskal","year":"2022","unstructured":"Klimiec-Moskal E, Quirke M, Leite MI (2022) Comorbidities in older patients with myasthenia gravis\u2014Comparison between early- and late-onset disease. Acta Neurol Scand 145:371\u2013374. https:\/\/doi.org\/10.1111\/ane.13549","journal-title":"Acta Neurol Scand"},{"key":"12922_CR152","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","volume":"33","author":"Z Safipour","year":"2022","unstructured":"Safipour Z, van der Zanden R, van den Bergh J et al (2022) The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis. Osteoporos Int 33:649\u2013658","journal-title":"Osteoporos Int"},{"key":"12922_CR153","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1007\/s00415-023-11925-6","volume":"270","author":"J-B Chanson","year":"2023","unstructured":"Chanson J-B, Bouhour F, Aub\u00e9-Nathier A-C et al (2023) Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study. J Neurol 270:5819\u20135826. https:\/\/doi.org\/10.1007\/s00415-023-11925-6","journal-title":"J Neurol"},{"key":"12922_CR154","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mus.26876","volume":"62","author":"SK Sahai","year":"2020","unstructured":"Sahai SK, Maghzi AH, Lewis RA (2020) Rituximab in late-onset myasthenia gravis is safe and effective. Muscle Nerve 62:377\u2013380. https:\/\/doi.org\/10.1002\/mus.26876","journal-title":"Muscle Nerve"},{"key":"12922_CR155","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20925","author":"S Thietart","year":"2022","unstructured":"Thietart S, Karras A, Augusto JF et al (2022) Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.20925","journal-title":"JAMA Netw Open"},{"key":"12922_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/science.186.4158.55","author":"RR Almon","year":"1974","unstructured":"Almon RR, Andrew CG, Appel SH (1974) Serum globulin in myasthenia gravis: inhibition of \u03b1-bungarotoxin binding to acetylcholine receptors. Science. https:\/\/doi.org\/10.1126\/science.186.4158.55","journal-title":"Science"},{"key":"12922_CR157","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S et al (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952. https:\/\/doi.org\/10.1093\/brain\/awn092","journal-title":"Brain"},{"key":"12922_CR158","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0203","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S et al (2015) Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0203","journal-title":"JAMA Neurol"},{"key":"12922_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577850","author":"G Masi","year":"2022","unstructured":"Masi G, Li Y, Karatz T et al (2022) The clinical need for clustered AChR cell-based assay testing of seronegative MG. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577850","journal-title":"J Neuroimmunol"},{"key":"12922_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000200038","volume":"10","author":"G Spagni","year":"2023","unstructured":"Spagni G, Gastaldi M, Businaro P et al (2023) Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis. Neurol Neuroimmunol NeuroInflammation 10:1\u20137. https:\/\/doi.org\/10.1212\/NXI.0000000000200038","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"12922_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lanwpc.2023.100846","volume":"38","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang C, Chang T et al (2023) A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study. Lancet Reg Heal West Pacific 38:1\u20139. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100846","journal-title":"Lancet Reg Heal West Pacific"},{"key":"12922_CR162","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"12922_CR163","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","volume":"348","author":"I Matthews","year":"2004","unstructured":"Matthews I, Chen S, Hewer R et al (2004) Muscle-specific receptor tyrosine kinase autoantibodies\u2013A new immunoprecipitation assay. Clin Chim Acta 348:95\u201399. https:\/\/doi.org\/10.1016\/j.cccn.2004.05.008","journal-title":"Clin Chim Acta"},{"key":"12922_CR164","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D et al (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55:580\u2013584. https:\/\/doi.org\/10.1002\/ana.20061","journal-title":"Ann Neurol"},{"key":"12922_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11112098","author":"CM Gambino","year":"2021","unstructured":"Gambino CM, Agnello L, Lo Sasso B et al (2021) Comparative analysis of BIOCHIP mosaic-based indirect immunofluorescence with enzyme-linked immunosorbent assay for diagnosing myasthenia Gravis. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics11112098","journal-title":"Diagnostics"},{"key":"12922_CR166","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0205","author":"D Villalta","year":"2023","unstructured":"Villalta D, Fabris M, Verriello L et al (2023) Acetylcholine receptor and muscle-specific tyrosine kinase antibodies detection: is it time for a change? Clin Chem Lab Med. https:\/\/doi.org\/10.1515\/cclm-2023-0205","journal-title":"Clin Chem Lab Med"},{"key":"12922_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2024.113627","author":"K Luong","year":"2024","unstructured":"Luong K, Lozier BK, Novis CL et al (2024) Comparison of three methods for the detection of antibodies against muscle-specific kinase. J Immunol Meth. https:\/\/doi.org\/10.1016\/j.jim.2024.113627","journal-title":"J Immunol Meth"},{"key":"12922_CR168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083924","author":"S George","year":"2014","unstructured":"George S, Paulick S, Kn\u00fctter I et al (2014) Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of Myasthenia Gravis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0083924","journal-title":"PLoS ONE"},{"key":"12922_CR169","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","volume":"301","author":"L Yang","year":"2011","unstructured":"Yang L, Maxwell S, Leite MI et al (2011) Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci 301:71\u201376. https:\/\/doi.org\/10.1016\/j.jns.2010.10.023","journal-title":"J Neurol Sci"},{"key":"12922_CR170","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","volume":"343","author":"T Chang","year":"2014","unstructured":"Chang T, Leite MI, Senanayake S et al (2014) Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. J Neurol Sci 343:82\u201387. https:\/\/doi.org\/10.1016\/j.jns.2014.05.037","journal-title":"J Neurol Sci"},{"key":"12922_CR171","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/mus.25154","volume":"54","author":"S Huda","year":"2016","unstructured":"Huda S, Woodhall MR, Vincent A, Heckmann JM (2016) Characteristics Of acetylcholine-receptor-antibody\u2013negative myasthenia gravis in a South African cohort. Mus Nerve 54:1023\u20131029. https:\/\/doi.org\/10.1002\/mus.25154","journal-title":"Mus Nerve"},{"key":"12922_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000357","volume":"4","author":"S Huda","year":"2017","unstructured":"Huda S, Waters P, Woodhall M et al (2017) IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol NeuroInflammation 4:1\u20139. https:\/\/doi.org\/10.1212\/NXI.0000000000000357","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"12922_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1052-3057(10)80125-9","volume":"3","author":"CR Gomez","year":"1993","unstructured":"Gomez CR (1993) Editorial: time is brain! J Stroke Cerebrovasc Dis 3:1\u20132. https:\/\/doi.org\/10.1016\/S1052-3057(10)80125-9","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"12922_CR174","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/mus.27838","volume":"68","author":"SH Wong","year":"2023","unstructured":"Wong SH, Petzold A (2023) Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels. Mus Nerve 68:91\u201394. https:\/\/doi.org\/10.1002\/mus.27838","journal-title":"Mus Nerve"},{"key":"12922_CR175","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00234-021-02753-4","volume":"63","author":"G Velonakis","year":"2021","unstructured":"Velonakis G, Papadopoulos VE, Karavasilis E et al (2021) MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis. Neuroradiology 63:1531\u20131538. https:\/\/doi.org\/10.1007\/s00234-021-02753-4","journal-title":"Neuroradiology"},{"key":"12922_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Herbst R (2019) Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. https:\/\/doi.org\/10.3390\/cells8070671","journal-title":"Cells"},{"key":"12922_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158058","author":"SR Iyer","year":"2021","unstructured":"Iyer SR, Shah SB, Lovering RM (2021) The neuromuscular junction: roles in aging and neuromuscular disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22158058","journal-title":"Int J Mol Sci"},{"key":"12922_CR178","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/mus.28038","volume":"69","author":"KG Gwathmey","year":"2024","unstructured":"Gwathmey KG, Ding H, Hehir M, Silvestri N (2024) How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Mus Nerve 69:389\u2013396. https:\/\/doi.org\/10.1002\/mus.28038","journal-title":"Mus Nerve"},{"key":"12922_CR179","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jnnp.35.3.311","volume":"35","author":"B Brownell","year":"1972","unstructured":"Brownell B, Oppenheimer DR, Spalding JM (1972) Neurogenic muscle atrophy in myasthenia gravis. J Neurol Neurosurg Psychiat 35:311\u2013322. https:\/\/doi.org\/10.1136\/jnnp.35.3.311","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"12922_CR180","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/acr.22314","volume":"66","author":"S Payet","year":"2014","unstructured":"Payet S, Soubrier M, Perrodeau E et al (2014) Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French society of rheumatology registry. Arthritis Care Res 66:1289\u20131295","journal-title":"Arthritis Care Res"},{"key":"12922_CR181","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40266-020-00782-x","volume":"37","author":"P Mielnik","year":"2020","unstructured":"Mielnik P, Sexton J, Lie E et al (2020) Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register. Drug Aging 37:617\u2013626. https:\/\/doi.org\/10.1007\/s40266-020-00782-x","journal-title":"Drug Aging"},{"key":"12922_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000200164","volume":"10","author":"AM Langer-Gould","year":"2023","unstructured":"Langer-Gould AM, Smith JB, Gonzales EG et al (2023) Multiple sclerosis, disease-modifying therapies, and infections. Neurol Neuroimmunol neuroinflammation 10:1\u201312. https:\/\/doi.org\/10.1212\/NXI.0000000000200164","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"12922_CR183","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3818","author":"FS Ismail","year":"2024","unstructured":"Ismail FS, Gallus M, Meuth SG et al (2024) Current and future roles of chimeric antigen receptor T-cell therapy in neurology a review. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3818","journal-title":"JAMA Neurol"},{"key":"12922_CR184","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D et al (2023) Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol 22:1104\u20131105. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7","journal-title":"Lancet Neurol"},{"key":"12922_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.04.014","author":"J Motte","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C et al (2024) Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2024.04.014","journal-title":"Neuron"},{"key":"12922_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","author":"J Wickel","year":"2024","unstructured":"Wickel J, Schnetzke U, Klink A et al (2024) Anti-CD19 CAR-T cells are effective in severe idiopathic lambert-eaton myasthenic syndrome. Cell Report Med. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101794","journal-title":"Cell Report Med"},{"key":"12922_CR187","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000531224","volume":"7","author":"M Lootus","year":"2023","unstructured":"Lootus M, Beatson L, Atwood L et al (2023) Development and assessment of an artificial intelligence-based tool for ptosis measurement in adult myasthenia gravis patients using selfie video clips recorded on smartphones. Digit Biomark 7:63\u201373. https:\/\/doi.org\/10.1159\/000531224","journal-title":"Digit Biomark"},{"key":"12922_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42682-9","author":"J \u00c5kesson","year":"2023","unstructured":"\u00c5kesson J, Hojjati S, Hellberg S et al (2023) Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-42682-9","journal-title":"Nat Commun"},{"key":"12922_CR189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864231154976","volume":"16","author":"H Zhong","year":"2023","unstructured":"Zhong H, Ruan Z, Yan C et al (2023) Short-term outcome prediction for myasthenia gravis: an explainable machine learning model. Ther Adv Neurol Disord 16:1\u201316. https:\/\/doi.org\/10.1177\/17562864231154976","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12922-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:40:18Z","timestamp":1742233218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12922-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":189,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12922"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12922-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IMM and MA have no nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"226"}}